Alvogen Strikes Deals For Pfenex’ Teriparatide
Meanwhile, Pfenex Reports Positive Results In US Equivalence Study
Alvogen has signed marketing deals with local firms in Canada, Israel and South Korea for the teriparatide drug it has licensed from Pfenex. In the US, Pfenex has just completed a human factors study it feels should support a therapeutic equivalence rating for its Forteo rival.
You may also be interested in...
Alvotech and JAMP Pharma have struck a partnership deal to market five biosimilars in Canada that have a combined current branded market value of more than $2bn annually.
Israel’s Kamada has struck a licensing deal with Alvotech that gives it rights to several of the firm’s biosimilars in its domestic market. The first launch, of the teriparatide biosimilar co-developed with Pfenex, is planned for 2022.
Daiichi Sankyo obtains rights to antiemetic Nasea and the anti-hypertension drugs Perdipine and Oldeca. Mitsubishi Tanabe licenses Asian rights to Viela’s inebilizumab for a rare eye disorder.